Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Despite Pricing Pressure, Humira Performing Strongly Across Most Metrics, Abbvie Says

Executive Summary

Humira continues its strong growth pace through volume gains and market share across therapeutic categories, CEO Gonzalez says, while leukemia drug Imbruvica also had a solid third quarter.

You may also be interested in...

Amgen’s Biggest Seller Enbrel Hit By Pricing Pressures, Competition

Amgen signaled future declines in revenue for its top-selling product Enbrel during its third quarter conference call as payer pressure on drug pricing and competition mounts.

Another Strong Quarter For AbbVie, But How Long Will Good Times Last?

With continued strong growth for Humira, AbbVie doubles down on confidence to protect the franchise with IP strategy. Imbruvica and Viekira Pak show growth, although the latter is flourishing only ex-US.

Imbruvica Boosts CLL Lead With First-Line Claim

AbbVie Inc. and Johnson & Johnson's BTK inhibitor Imbruvica (ibrutinib) has reinforced its lead position in the chronic lymphocytic leukemia market with a first-line indication from FDA.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts